The U.S. Food and Drug Administration (FDA) siad Friday it has approved Yondelis (trabectedin), a chemotherapy, for the treatment of liposarcoma and leiomyosarcoma, specific soft tissue sarcomas (STS), that are not able to be removed by surgery or are advanced (metastatic).
The treatment is indicated for patients who have received chemotherapy that contained anthracycline.
Liposarcoma and leiomyosarcoma are specific types of STS that occur in fat cells (liposarcoma) or smooth muscle cells (leiomyosarcoma).
“The treatment of advanced or metastatic soft tissue sarcoma represents a difficult challenge with few effective therapeutic choices available for patients,” FDA Center for Drug Evaluation and Research
Office of Hematology and Oncology Products Director Richard Pazdur said. “(The) approval of Yondelis provides a treatment option for advanced or metastatic liposarcoma and leiomyosarcoma.”
Yondelis was the subject of a random test of 518 clinical trial participants.
Yondelis carries risks of severe and fatal blood infections (neutropenic sepsis), muscle tissue breakdown (rhabdomyolysis), liver damage (hepatotoxicity), leakage around the vein or catheter (extravasation), tissue necrosis (breakdown) and heart failure (cardiomyopathy).
FDA approves Yondelis for certain types of sarcoma
Organizations in this Story
Want to get notified whenever we write about U.S. Food and Drug Administration (FDA) ?
Next time we write about U.S. Food and Drug Administration (FDA), we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts